Temporarily switching from oral to intravenous selexipag in patients with pulmonary arterial hypertension: safety, tolerability, and pharmacokinetic results from an open-label, phase III study

Hans Klose1*, Kelly M. Chin2, Ralf Ewert3, Henning Gall4, Joseph Parambil5, David Poch6, Hans-Jürgen Seyfarth7, Lene N. Axelsen8, Shu-Fang Hsu Schmitz8, Claudia Stein8 and Ioana R. Preston9

Abstract
Background: The oral IP receptor agonist selexipag is approved for the long-term treatment of pulmonary arterial hypertension (PAH). Treatment interruptions should be avoided due to the progressive nature of the disease. An intravenous (IV) formulation of selexipag was developed to provide a treatment option for short-term interruptions to oral selexipag. In this prospective, multicenter, open-label study, the safety, tolerability, and pharmacokinetics of temporarily switching between oral and IV selexipag were investigated (NCT03187678, ClinicalTrials.gov).

Methods: PAH patients receiving stable oral selexipag doses were enrolled. Following three consecutive IV selexipag infusions patients resumed oral selexipag. Corresponding IV and oral doses were selected to achieve comparable exposure to the active metabolite of selexipag. Safety outcomes were monitored throughout, and pharmacokinetic samples were obtained after oral and IV administration.

Results: All 20 patients completed the study. Fifteen patients had adverse events (AEs), most were mild, and none resulted in discontinuation. Headache was the most common AE throughout the study (four patients). Three serious AEs occurred in two patients with underlying comorbidities when oral dosing had resumed. There were no changes in WHO functional class for any patient and no clinically symptomatic changes in blood pressure were observed. Comparable exposure to the active metabolite of selexipag was demonstrated following corresponding oral and IV selexipag doses.

Conclusions: Temporarily switching between corresponding doses of oral and IV selexipag was well-tolerated with no unexpected safety findings and comparable exposure to the active metabolite. Treatment with IV selexipag is a feasible option to bridge temporary oral selexipag treatment interruptions.

Keywords: Selexipag, Pulmonary arterial hypertension, Pharmacokinetics, Treatment interruptions, Intravenous

Introduction
Pulmonary arterial hypertension (PAH) is a progressive, debilitating and potentially fatal disease [1]. Several pharmacotherapies are approved that target the main pathways involved in the pathogenesis of PAH [1].
The prostacyclin pathway is one of the established therapeutic targets [2], for which available treatment options include intravenous (IV) prostacyclin (e.g. epoprostenol), parenteral and non-parenteral prostacyclin analogs (e.g. iloprost and treprostinil), and an oral selective prostacyclin IP receptor agonist (selexipag) [1, 3–6]. Selexipag was approved for the treatment of adult patients with PAH based on the event-driven GRIPHON study. In the pivotal GRIPHON study, selexipag was up-titrated to the individual patient’s highest tolerated dose, from 200 µg to a maximum of 1600 µg twice daily (bid), in order to achieve the appropriate dose and manage prostacyclin-associated side-effects [3, 6].

Uninterrupted treatment is considered important to maintain the therapeutic effect of PAH-specific therapies [7]. In clinical practice, however, patients may temporarily not be able to swallow, for example when hospitalized for elective surgery, and may therefore be unable to receive administration of oral therapies [7]. Abrupt oral selexipag interruptions were not associated with acute deterioration of PAH in the GRIPHON study [8]. However, the option to continue selexipag treatment at the same dose level with an IV formulation for patients who are already receiving a stable oral dose, is considered important and would avoid the need to re-titrate oral selexipag upon re-initiation [7]. Therefore, bridging short-term treatment interruptions of oral selexipag with IV selexipag infusions would maintain the treatment effect and avoid the need to re-titrate selexipag after re-initiation or change therapy.

Following administration, selexipag is hydrolyzed by carboxylesterases to the active metabolite (JNJ-68006861 [also known as ACT-333679]), which is approximately 37-fold more potent than selexipag and therefore the main contributor to the pharmacological effect [6, 9–11]. Therefore, it is assumed that achieving similar exposure to the active metabolite following either IV or oral administration of selexipag will result in comparable efficacy. Based on the results of a selexipag absolute bioavailability study in healthy adult males [12], IV selexipag doses should be 12.5% higher than the oral selexipag doses and administered as bid infusions to achieve comparable exposure to the active metabolite (Table 1).

The objective of this study was to assess the safety, tolerability, and pharmacokinetics of temporarily switching between corresponding oral and IV doses of selexipag in patients with PAH on stable oral selexipag treatment.

**Methods**

**Study design**

This was a prospective, multicenter, open-label, single-sequence, cross-over, phase 3 study in patients with PAH (NCT03187678). The study comprised a 28-day screening phase, followed by a 12-day treatment and observation phase, and a subsequent 30-day safety follow-up phase (Fig. 1). The treatment and observation phase was further divided into three periods. Patients were hospitalized during Periods 1 and 2. In Period 1 patients received their stable oral dose of selexipag bid (morning and evening of Day 1). In Period 2 patients received three infusions of corresponding IV selexipag doses (morning and evening of Day 2, and morning of Day 3). In Period 3, patients resumed their stable oral selexipag dose bid in the evening of Day 3 for 9 days, which was continued through the safety follow-up. The study was approved by an independent ethics committee or institutional review board at each site, and all patients provided written informed consent prior to enrolment.

| Oral selexipag dose, µg bid | IV selexipag dose, µg bid | Number of patients at dose level, n (%) |
|-----------------------------|---------------------------|----------------------------------------|
| 200                         | 225                       | 0                                      |
| 400                         | 450                       | 1 (5.0)                                |
| 600                         | 675                       | 2 (10.0)                               |
| 800                         | 900                       | 2 (10.0)                               |
| 1000                        | 1125                      | 3 (15.0)                               |
| 1200                        | 1350                      | 2 (10.0)                               |
| 1400                        | 1575                      | 1 (5.0)                                |
| 1600                        | 1800                      | 9 (45.0)                               |

*bid twice daily, IV intravenous*
Study intervention

IV selexipag doses corresponding to the approved oral dose levels based on exposure to the active metabolite (IV dose 12.5% higher than the oral dose; Table 1) were administered. Selexipag in dry powder form was reconstituted and diluted with sterile 0.9% NaCl solution to the appropriate IV dose. Each IV selexipag dose was administered as a 50 mL solution using an infusion pump and 50 mL syringe for a total of 87 min. Each administration was infused at 20 mL/h for the first 15 min (5 mL) and 37.5 mL/h for the remaining 72 min (45 mL). The initial, slower infusion rate was a precautionary measure to assess any tolerability issues. More detailed methods can be found in the supplementary material.

Outcomes and assessments

The objectives of this study were to assess the safety and tolerability of temporarily switching from a stable oral to an IV selexipag dose, and to evaluate the pharmacokinetics of selexipag and the active metabolite at steady state following both oral and IV administration.

Safety and tolerability evaluations included adverse events (AEs), discontinuations due to AEs, and serious AEs (SAEs). SBP and diastolic blood pressure (DBP) were monitored before oral administration on Day 1 (Period 1), before (pre-dose), during (25 and 87 min after infusion start) and after (4, 6, 8, and 12 h post-infusion start) the morning IV infusions on Day 2 and Day 3 (Period 2), and on Day 12 (Period 3). Electrocardiograms (ECG) were recorded on Day 1 before oral selexipag administration (Period 1), immediately before infusion start and within 30 min of completing each IV selexipag infusion on Day 2 and 3 (Period 2), and on Day 12 (Period 3). Hematology and blood chemistry samples were collected at screening, on Day 1, 3, and 12. WHO FC was assessed on Day 1, 3 (at the end of the third IV infusion), and 12.

Pharmacokinetic sampling was performed pre-dose, and at 1, 2, 4, 6, 8, and 12 h(s) post-oral morning administration on Day 1 (Period 1), and at pre-dose, 25 min, 87 min, 4, 6, 8, and 12 h post-IV selexipag infusion start of the morning administration on Day 3 (Period 2). The pharmacokinetic endpoints assessed for selexipag and the active metabolite were the area under the concentration–time curve (AUC) during a dose interval at steady state ($AUC_{ss}$), the maximum plasma concentration at steady state ($C_{max, ss}$), the time to reach maximum plasma concentration at steady state ($t_{max, ss}$), and combined $AUC_{ss}$ of selexipag and ACT-333679. $cAUC_{ss}$ was defined as the potency-weighted average of $AUC_{ss}$ of selexipag and ACT-333679 and calculated as $cAUC_{ss} = 1/38 \times AUC_{ss} + 37/38 \times AUC_{ss}$.

Statistical analysis

For analysis of safety and tolerability, discrete data were summarized with frequency and percentage, while continuous data were summarized with descriptive statistics. Detailed statistical methods are included in the supplementary material. Pharmacokinetic parameters for selexipag and ACT-333679 were derived by non-compartmental analysis of the concentration–time profiles using Phoenix® WinNonlin® 6.4 (Certara, Princeton, NJ, USA). For all analyses SAS® version 9.4 (SAS Institute, Cary, NC, USA) was used. Results were dose normalized to the lowest selexipag dose (oral: 200 µg; IV: 225 µg), by dividing the respective parameter by the actual dose for that patient and multiplying by 200 (oral) or 225 (IV).

Three plasma concentrations of selexipag (two patients) and ACT-333679 (one patient) were excluded in the primary analyses as the concentrations were considered implausible when compared with the remaining measurements from the same patients. As the underlying root cause could not be identified, sensitivity...
analyses for $AUC_{T,ss}$ and dose proportionality were performed to assess whether the exclusion of those three samples in the primary analysis affected the overall conclusion.

**Results**

**Patient disposition and demographics**

Twenty patients with PAH were enrolled and completed the study (Additional file 1: Figure S1). During the study, all patients received their planned oral and IV selexipag doses. The mean (SD) patient age was 56.5 (9.43) years and 80% were female. At baseline, most patients were in WHO FC II (65%) or FC III (30%). All patients were receiving at least one other oral PAH-specific therapy in addition to oral selexipag at baseline (Table 2). Patients were taking oral selexipag at a maintenance dose between 400–1600 µg bid (Table 1) for a median duration of 14.46 (range: 2.1; 24.1) months prior to the first IV selexipag infusion (Table 2).

**Safety and tolerability**

During the study 15 patients had at least one AE (Table 3). Across all study periods, eight patients had mild intensity AEs and five patients had moderate intensity AEs, with severe intensity AEs reported in one patient. The AEs that were reported for at least two patients were headache (four patients), infusion site erythema (two patients), and peripheral edema (two patients) (Table 3). Both events of peripheral edema were considered as not related to IV selexipag, as judged by the investigator.

For eight patients, at least one AE was considered to be IV selexipag treatment-related (Table 4). Most of the IV selexipag-related AEs were prostacyclin-associated or infusion site reactions. Prostacyclin-associated AEs were reported during IV selexipag treatment and after re-initiation of oral selexipag in seven out of 20 patients (Table 4). None were reported as severe, serious, or resulted in IV or oral selexipag treatment discontinuation. There were no discontinuations due to AEs. For two patients, AEs related to infusion site reactions were reported. One patient had infusion site erythema and swelling, which started during the final infusion and were categorized as mild in intensity. Another patient had mild-to-moderate infusion site erythema starting between the first and second infusions. All infusion site reactions resolved within 4 days after the last infusion.

Three SAEs occurred in two patients after oral selexipag re-initiation (Table 4). One patient with a history of type 2 diabetes and cataracts developed retinal detachment and unilateral blindness, which were considered by the investigator to be severe and IV selexipag treatment-related. Vision reportedly improved to 80% following treatment. Another patient experienced right ventricular failure due to a respiratory infection. This event resolved without sequelae. Both patients continued to receive oral selexipag.

During the study, there were no changes in the WHO FC status for all patients and no deaths or discontinuations of treatment were reported.

No symptomatic blood pressure changes or AEs of hypotension were reported at any time during the study. Mean changes in blood pressure during the 12 h following initiation of the morning IV infusion ranged between $-7.0 \text{ mmHg}$ to $-2.1 \text{ mmHg}$ for SBP and $-3.1 \text{ mmHg}$ to $+0.5 \text{ mmHg}$ for DBP on Day 2, and $-2.7$ to $+2.4 \text{ mmHg}$ for SBP and $-3.6 \text{ mmHg}$ to $+2.1 \text{ mmHg}$ for DBP on Day 3 (Fig. 2).

Mean changes from pre-dose in QTcF interval at 30 min post-dose for the first, second and third IV infusions were 0.4, 3.3, and 0.4 ms, respectively. There were

---

**Table 2 Baseline demographics and disease characteristics**

| Characteristic | Total, N = 20 |
|---------------|--------------|
| **Sex** | |
| Female | 16 (80.0) |
| Male | 4 (20.0) |
| **Age, years, mean (SD)** | 56.5 (9.43) |
| **BMI, kg/m², mean (SD)** | 28.5 (6.50) |
| **Country** | |
| Germany | 13 (65.0) |
| USA | 7 (35.0) |
| **Time since PAH diagnosis at baseline, months, mean (SD)** | 107.8 (90.83) |
| **PAH etiology, n (%)** | |
| Idiopathic or heritable PAH | 14 (70.0) |
| PAH associated with CTD | 4 (20.0) |
| PAH associated with portal hypertension | 1 (5.0) |
| PAH associated with CHD | 1 (5.0) |
| **WHO functional class, n (%)** | |
| I | 1 (5.0) |
| II | 13 (65.0) |
| III | 6 (30.0) |
| **Duration on oral selexipag dose prior to first IV infusion, months, median (range)** | 14.5 (2.1, 24.1) |
| **Ongoing PAH therapies at baseline, n (%)** | |
| PDE-5 inhibitor | 1 (5.0) |
| sGC stimulator | 1 (5.0) |
| ERA + PDE-5 inhibitor | 13 (65.0) |
| ERA + sGC stimulator | 5 (25.0) |

*BMI* body mass index, *CHD* congenital heart disease, *CTD* connective tissue disorder, *ERA* endothelin receptor antagonist, *IV* intravenous, *PAH* pulmonary arterial hypertension, *PDE-5* phosphodiesterase-5, *SD* standard deviation, *sGC* soluble guanylate cyclase, *WHO* World Health Organization
no consistent trends for any qualitative or quantitative ECG abnormalities observed throughout the 3 IV infusions of selexipag.

For hemoglobin, a small mean change from baseline (129.4 g/L) to Day 3 of −5.7 g/L was observed. At Day 12 ± 2 days, the mean change was +1.2 g/L. The changes between the visits were suggestive of normal variability of this parameter rather than a trend. None of the post-baseline individual changes in hemoglobin levels were reported as an AE. Changes from baseline in other hematology and clinical chemistry variables were unremarkable.

**Pharmacokinetics**

The tested corresponding doses of oral and IV selexipag resulted in comparable exposure to the active metabolite of selexipag (Fig. 3 and on a semi-logarithmic scale in Additional file 1: Figure S2). A full summary of dose-normalized derived endpoints are shown in Additional file 1: Table S2. Exposure (AUC\textsubscript{T, ss} and C\textsubscript{max, ss}) of
selexipag were approximately two-fold higher following IV versus oral administration (ratio of geometric means [RGM]: \( \text{AUC}_{\text{T}}, \text{ss} = 2.13; \text{C}_{\text{max}, \text{ss}} = 1.98\)). While \( \text{AUC}_{\text{T}, \text{ss}} \) and \( \text{C}_{\text{max}, \text{ss}} \) of the active metabolite were comparable (RGM: \( \text{AUC}_{\text{T}, \text{ss}} = 0.80; \text{C}_{\text{max, ss}} = 0.79\)) (Fig. 3; Additional file 1: Table S2). The RGM for the combined AUC

| Table 4 Incidence of AEs reported during the study | Period 1 (24 h), N = 20 | Period 2 (36 h), N = 20 | Period 3 + follow-up (up to 37 days), N = 20 |
|-------------------------------------------------|--------------------------|--------------------------|-----------------------------------------------|
| Administration route                            | Oral                     | IV infusion              | Oral                                          |
| Patients with \( \geq 1 \) AE                  | 2 (10.0)                 | 10 (50.0)                | 8 (40.0)                                      |
| Patients with \( \geq 1 \) SAE                 | 0                        | 0                        | 2 (10.0)                                      |
| Patients with an AE leading to discontinuation  | 0                        | 0                        | 0                                             |
| Patients with \( \geq 1 \) IV selexipag-related AE | N/A                     | 7 (35.0)\(^a\)          | 2 (10.0)\(^b\)                               |
| Patients with \( \geq 1 \) prostacyclin-associated AE | 0                        | 7 (35.0)\(^a\)          | 1 (5.0)\(^c\)                                |
| Patients with \( \geq 1 \) AE related to infusion site reactions | N/A                     | 2 (10.0)                | 0                                             |
| Patients with prostacyclin-associated AE leading to discontinuation | 0                        | 0                        | 0                                             |
| Deaths                                          | 0                        | 0                        | 0                                             |

Data are n (%)

AE, adverse event; IV, intravenous; SAE, serious adverse event

\(^a\) Six patients experienced both IV selexipag-related and prostacyclin-related AEs during Period 2

\(^b\) One patient experienced IV selexipag-related AEs during both Period 2 and Period 3, the other patient experienced IV selexipag-related AEs during Period 3 only

\(^c\) This patient also experienced prostacyclin-associated AEs during Period 2

Fig. 2 Mean (bold red line) and individual changes in systolic and diastolic blood pressure from pre-dose values during IV infusion 1 (Day 2) and IV infusion 3 (Day 3). IV, intravenous
adjusted from the relative potencies of selexipag and the active metabolite (cAUC_{T\_ss}) was 0.82 (Additional file 1: Table S2). Consistent results were obtained in a sensitivity analysis including the three implausible values (Additional file 1: Table S3).

\( t_{\text{max, ss}} \) was similar following oral and IV selexipag administration, for both selexipag and the active metabolite (Fig. 3; Additional file 1: Table S2). Dose proportionality following IV selexipag infusion was assessed for both selexipag and the active metabolite using the power model [13] (selexipag: exponent = 0.798, 90% CI: 0.387, 1.209; ACT-333679 exponent = 0.697, 90% CI: –0.003, 1.397; Additional file 1: Figure S3). Consistent results were obtained in a sensitivity analysis including implausible values.

**Discussion**

In this study, 20 patients with PAH who were receiving oral selexipag at a stable maintenance dose were switched to corresponding IV selexipag doses for three infusions. The switch from oral to IV selexipag and back was well tolerated with comparable exposure to the active metabolite of selexipag.

The overall safety results reported in each period in this study are consistent with previous studies of oral [3–5] and IV selexipag [12], and the switch between the two formulations was well tolerated and did not result in any unexpected safety findings. The AEs reported were mostly mild in intensity and were mainly prostacyclin-associated or related to infusion site reactions. The small number of reported infusion site reactions support peripheral IV access for short-term administration. The SAES reported for two patients following re-initiation of oral selexipag or during the safety follow-up phase were confounded by underlying comorbidities and resolved without sequelae, and both patients continued with oral selexipag treatment. There was no evidence of any change in the clinical condition during the short-term switch to IV selexipag, on the basis of WHO FC and the AE profile. Hypotension is commonly reported with therapies targeting the prostacyclin pathway [14] and was reported as an AE in 5% of selexipag-treated GRIPHON patients [3]. However, clinically symptomatic blood pressure changes were not observed in this study.

Based on pharmacokinetic assessments, the tested IV doses that were 12.5% higher than the corresponding oral doses provided comparable exposure to the active metabolite after oral and IV selexipag administration. The exposure to selexipag increased 2.13-fold following IV versus oral administration, as expected based on the previous bioavailability study [12]. The increase in selexipag exposure is, however, considered to be of limited clinical relevance due to its relatively low potency compared with the active metabolite, which is supported by the safety results observed in the clinical study.

The pharmacokinetics of selexipag and its active metabolite are known to be dose-proportional for multiple oral doses up to 1800 µg bid [15]. In agreement with this, the available data in this present study showed no obvious deviations from dose proportionality following IV administration for either selexipag or the active metabolite within the tested IV dose range of 450–1800 µg bid. Overall, the observed exposure to selexipag and the active metabolite following IV administration is suitable for temporarily bridging oral treatment interruptions in PAH patients.

The combined pharmacokinetic and safety results reported support the use of the IV formulation of selexipag as a suitable bridging option for temporary treatment interruptions of oral selexipag and may benefit patients by allowing them to remain on selexipag treatment and maintain exposure to the active metabolite. In addition, this avoids the need to either repeat
up-titration of oral selexipag or switch to a parenteral formulation of another IP-receptor agonist, which will require a route for continuous infusion.

This study has some limitations due to the small sample size, the short treatment duration and the potential reporting bias of AEs during IV selexipag treatment because of the open-label nature of the study. Vital signs were not monitored during or following the evening IV infusion on Day 2, therefore changes in blood pressure during this time period may not have been observed, however, no AEs of hypotension were reported at any time during the study. Finally, the number of pharmacokinetic samples collected per patient was reduced to a minimum in consideration of the patient burden. However, the pharmacokinetic data from the available time points demonstrate comparable exposure to the active metabolite after IV and oral selexipag administration.

Conclusions
The switch from oral to IV selexipag and back was well tolerated and the safety findings are consistent with those known following treatment with oral selexipag. Exposure to the active metabolite was comparable following oral and IV selexipag administration when applying an IV selexipag dose that is 12.5% higher than the corresponding oral dose. The study results support the use of IV selexipag as a temporary option for PAH patients to avoid treatment interruptions during clinical scenarios in which the administration of oral selexipag is not possible.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12931-020-01594-8.

Acknowledgements
Medical writing assistance and editorial support were provided by Zoe Schäfer, PhD, of Watermeadow Medical (an Ashfield company, part of UDG Healthcare plc), and was funded by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson.

Authors’ contributions
HK, JP, DP, CS, IRP participated in the conception and design of the work. HK, KMC, RE, HG, DP, HJS, LNA, CS, IRP participated in the acquisition/collection of data. HK, KMC, RE, HG, DP, LNA, SHS, CS, IRP participated in the analysis/interpretation of the data. All authors drafted and/or revised the text, have approved this version for publication and are accountable for all aspects of the work. All authors read and approved the final manuscript.

Funding
Open Access funding enabled and organized by Projekt DEAL. This study was sponsored by Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson (Allschwil, Switzerland). The sponsor was involved in the conception and design of the study, analysis and interpretation of the data, critical revision of the manuscript, and approval for submission to the journal.

Availability of data and materials
The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinicaltrials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu.

Ethics approval and consent to participate
The study was approved by an independent ethics committee or institutional review board at each site, and all patients provided written informed consent prior to enrolment.

Consent for publication
Not applicable.

Competing interests
HK has received honoraria and/or other support from Bayer, Janssen Pharmaceutical Companies of Johnson & Johnson, MSD, OMT and United Therapeutics. KC has received honoraria and/or fees for consultancy and steering/adjudication committees from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer (through the University of California, San Diego), United Therapeutics and Gossamer Bio. KC’s institution has received grants, research support from Janssen Pharmaceutical Companies of Johnson & Johnson, Ironwood Pharmaceuticals, the National Institute of Health and Sonn Vive, and she has received financial/material support from the American Heart Association. RE has received honoraria and/or fees for consultancy from Janssen Pharmaceutical Companies of Johnson & Johnson, Bayer Vital and OMT and as a corporate board member for Actelion Pharmaceuticals Ltd, OMT and Novartis. RE has received grants from Janssen Pharmaceutical Companies of Johnson & Johnson, Boehringer Ingelheim, OMT, Berlin Chemie and Novartis. HG has received fees and/or honoraria and/or other support from Janssen Pharmaceutical Companies of Johnson & Johnson, AstraZeneca, Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Lilly, MSD, Novartis, OMT, Pfizer and United Therapeutics. JP has nothing to declare. DP has received consultant/speaker’s bureau honoraria and/or fees from Bayer. HJS has received advisory board honoraria and/or fees and/or grants and research support from Janssen Pharmaceutical Companies of Johnson & Johnson and has received financial support and/or speaker honoraria from BayerGlaxoSmithKline. LNA, SHS and CS are employees of Actelion Pharmaceuticals Ltd, a Janssen Pharmaceutical Company of Johnson & Johnson; SHS is a stock holder in Novartis, Alcon, and stock option holder in Janssen Pharmaceutical Companies of Johnson & Johnson, LNA is a stock holder in Novo Nordisk A/S and Zealând Pharma A/S and CS is stock holder in Novartis, Organovo, Idorsia Pharmaceuticals Ltd, and stock option holder in Janssen Pharmaceutical Companies of Johnson & John son. IRP has received consultant and scientific medical advisor honoraria and/or fees from Janssen Pharmaceutical Companies of Johnson & Johnson, Arena, Gilead, United Therapeutics, Liquidia, Pfizer and Acceleron. IRP’s institution has received grants and research support from Janssen Pharmaceutical Companies of Johnson & Johnson, Acceleron, Arena, Gilead, United Therapeutics, Liquidia and Bayer.

Author details
1 Department of Respiratory Medicine, Center of Oncology, University Medical Center Hamburg-Eppendorf, Martinistrasse S2, 20246 Hamburg, Germany. 2 Division of Pulmonary and Critical Care Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA. 3 Department of Respiratory Medicine, Clinic of Internal Medicine, Ernst Moritz Arndt University of Greifswald, Greifswald, Germany. 4 University of Giessen and Marburg Lung Center (UGMLC), Member of the German Center for Lung Research (DZL), Giessen, Germany. 5 Department of Pulmonary, Allergy and Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH, USA. 6 Department of Pulmonary Critical Care, University of California, San Diego, CA, USA. 7 Department of Respiratory Medicine, University of Leipzig, Leipzig, Germany. 8 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. 9 Pulmonary, Critical Care and Sleep Division, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA.
Received: 10 September 2020   Accepted: 1 December 2020
Published online: 03 February 2021

References
1. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67–119.
2. LeVarge BL. Prostanoid therapies in the management of pulmonary arterial hypertension. Ther Clin Risk Manag. 2015;11:535–47.
3. Sitbon O, Channick R, Chin KM, Frey A, Gaine S, Galiè N, Ghofrani H-A, Hoeper MM, Lang IM, Preiss R, et al. Selexipag for the treatment of pulmonary arterial hypertension. N Engl J Med. 2015;373:2522–33.
4. Beghetti M, Channick RN, Chin KM, Di Scala L, Gaine S, Ghofrani HA, Hoeper MM, Lang IM, McLaughlin W, Preiss R, et al. Selexipag treatment for pulmonary arterial hypertension associated with congenital heart disease after defect correction: insights from the randomised controlled GRIPHON study. Eur J Heart Fail. 2019;21:352–9.
5. Gaine S, Chin K, Coghlan G, Channick R, Di Scala L, Galiè N, Ghofrani H-A, Lang IM, McLaughlin V, Preiss R, et al. Selexipag for the treatment of connective tissue disease-associated pulmonary arterial hypertension. Eur Respir J. 2017;50:1602493.
6. Food and Drug Administration. Selexipag: highlights of prescribing information. Maryland: Food and Drug Administration; 2017.
7. Narechania S, Torbic H, Tonelli AR. Treatment discontinuation or interruption in pulmonary arterial hypertension. J Cardiovasc Pharmacol Ther. 2019;1074248419877409.
8. Preston IR, Channick RN, Chin K, Di Scala L, Farber HW, Gaine S, Galiè N, Ghofrani H-A, Hoeper MM, Lang IM, et al. Temporary treatment interruptions with oral selexipag in pulmonary arterial hypertension: Insights from the Prostacyclin (PGI2) Receptor Agonist in Pulmonary Arterial Hypertension (GRIPHON) study. J Heart Lung Transplant. 2018;37:401–8.
9. Kaufmann P, Okubo K, Bruderer S, Mant T, Yamada T, Dingemanse J, Mukai H. Pharmacokinetics and tolerability of the novel oral prostacyclin IP receptor agonist selexipag. Am J Cardiovasc Drugs. 2015;15:195–203.
10. Kaufmann P, Niglis S, Bruderer S, Segestaa J, Aanismaa P, Halabi A, Dingemanse J. Effect of lopinavir/ritonavir on the pharmacokinetics of selexipag, an oral prostacyclin receptor agonist and its active metabolite in healthy subjects. Br J Clin Pharmacol. 2015;80:670–7.
11. Bruderer S, Hurst N, Remenova T, Dingemanse J. Clinical pharmacology, efficacy, and safety of selexipag for the treatment of pulmonary arterial hypertension. Expert Opin Drug Saf. 2017;16:743–51.
12. Kaufmann P, Hurst N, Astruc B, Dingemanse J. Absolute oral bioavailability of selexipag, a novel oral prostacyclin IP receptor agonist. Eur J Clin Pharmacol. 2017;73:151–6.
13. Gough K, Hutchison M, Keene O, Byrom B, Ellis S, Lacey L, McKellar J. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK Joint Working Party. Drug Inf J. 1995;29:1039–48.
14. Kingman M, Archer-Chicko C, Bartlett M, Beckmann J, Hohsfield R, Lombardi S. Management of prostacyclin side effects in adult patients with pulmonary arterial hypertension. Pulmonary Circ. 2017;7:598–608.
15. Bruderer S, Hurst N, Kaufmann P, Dingemanse J. Multiple-dose up-titration study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of selexipag, an orally available selective prostacyclin receptor agonist, in healthy subjects. Pharmacology. 2014;94:148–56.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.